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Abstract
Aims/hypothesis Sulfonylureas are widely prescribed
glucose-lowering medications for diabetes, but the extent to
which they improve glycaemia is poorly documented. This
systematic review evaluates how sulfonylurea treatment
affects glycaemic control.
Methods Medline, EMBASE, the Cochrane Library and
clinical trials registries were searched to identify double-
blinded randomised controlled trials of fixed-dose sulfonyl-
urea monotherapy or sulfonylurea added on to other glucose-
lowering treatments. The primary outcome assessed was
change in HbA1c, and secondary outcomes were adverse
events, insulin dose and change in body weight.
Results Thirty-one trials with a median duration of 16 weeks
were included in the meta-analysis. Sulfonylurea monother-
apy (nine trials) lowered HbA1c by 1.51% (17 mmol/mol)
more than placebo (95% CI, 1.25, 1.78). Sulfonylureas
added to oral diabetes treatment (four trials) lowered HbA1c
by 1.62% (18 mmol/mol; 95% CI 1.0, 2.24) compared with
the other treatment, and sulfonylurea added to insulin (17
trials) lowered HbA1c by 0.46% (6 mmol/mol; 95% CI 0.24,
0.69) and lowered insulin dose. Higher sulfonylurea doses
did not reduce HbA1c more than lower doses. Sulfonylurea
treatment resulted in more hypoglycaemic events (RR 2.41,
95% CI 1.41, 4.10) but did not significantly affect the
number of other adverse events. Trial length, sulfonylurea
type and duration of diabetes contributed to heterogeneity.
Conclusions/interpretation Sulfonylurea monotherapy low-
ered HbA1c level more than previously reported, and we
found no evidence that increasing sulfonylurea doses
resulted in lower HbA1c. HbA1c is a surrogate endpoint,
and we were unable to examine long-term endpoints in these
predominately short-term trials, but sulfonylureas appear to
be associated with an increased risk of hypoglycaemic
events.
Keywords Clinical science . Human .Meta-analysis . Oral
pharmacological agents . Systematic review
Introduction
Sulfonylureas have long been established in the treatment of
diabetes and were the first oral glucose-lowering medica-
tions to be introduced into clinical practice. They are still
widely used and are the second-line recommended choice of
oral glucose-lowering treatment after metformin in the UK
[1]. There are still a large number of people who are taking
sulfonylureas, either as a first-line diabetes treatment or in
combination with another diabetes medication, accounting
for around 25% of newly initiated oral diabetes medications
[2]. Sulfonylureas act primarily by blocking ATP-sensitive
potassium channels in the pancreatic beta cells, which stim-
ulates insulin secretion [3]. A consensus report produced
jointly by American Diabetes Association and the European
Association for the Study of Diabetes reported that
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sulfonylureas lowered HbA1c by 1.5% (corresponding to
16 mmol/mol) [4], but this was based on results from a
single clinical trial [5]. Moreover, these results are based on a
single sulfonylurea in combination with metformin and there-
fore do not assess the effects of sulfonylurea monotherapy.
More recently, a systematic review examined the effect of
oral antidiabetic agents on HbA1c levels, although only six
trials of sulfonylurea were included [6]. This reported that
sulfonylurea treatment reduced HbA1c by around 1%
(corresponding to 11 mmol/mol). This systematic review
included trials of sulfonylureas in which dose changes were
permitted, and combined the results from trials of sulfonyl-
urea monotherapy, and sulfonylureas used in combination
with another oral medication or with insulin. In addition to
this, several other systematic reviews have assessed the
effect of sulfonylureas in combination with other medica-
tions on HbA1c level [7–9], and a meta-analysis examining
the effect of baseline HbA1c on efficacy of glucose-lowering
treatment [10]. There has, however, been no systematic
review that has separately examined the effects of sulfonyl-
urea as monotherapy, as an add-on to oral therapy or as an
add-on to insulin therapy.
We therefore conducted a systematic review of rando-
mised controlled trials to examine how much sulfonylurea
treatment reduces HbA1c on its own as a monotherapy
compared with placebo or added on to a background therapy
compared with the background therapy alone in people with
diabetes. We restricted our attention to fixed-dose sulfony-
lureas to better examine HbA1c lowering. In addition, the
dose–effect relationship of sulfonylureas was examined in
head-to-head trials of different sulfonylurea doses. The ef-
fect of sulfonylurea treatment on insulin dose requirement
and the total number of adverse events and hypoglycaemic
events in each treatment group were also compared.
Methods
We searched three databases, Medline, Embase and the
Cochrane Central Register of Controlled Trials, as well as
two clinical trials registries—Clinicaltrials.gov and the EU
Clinical Trials Register—up until 7 December 2012. We
identify randomised controlled trials of at least 12 weeks’
duration with no language restrictions (details of the Medline
search terms are given in the electronic supplementary mate-
rial [ESM] Text). A protocol for the systematic review has not
been published. Trials comparing fixed-dose sulfonylurea
treatment administered either as monotherapy vs placebo, as
an add-on to another fixed-dose oral glucose-lowering drug,
or as an add-on to insulin treatment, as well as trials that
compared two or more different doses of the same sulfonyl-
urea, were included in the review. Hand-searching of refer-
ence lists of relevant articles were also conducted.
Articles were reviewed by two reviewers. Inclusion cri-
teria were as follows: trials had to include patients with
diabetes, be randomised, be double-blinded, be at least
12 weeks in duration, have a fixed dose of sulfonylurea
either as monotherapy, as an add-on to another oral
glucose-lowering therapy or as an add-on to insulin therapy,
have the same sulfonylurea and background oral therapy
dose for each participant, and report participants’ HbA1c
levels after baseline.
Data extraction Data were extracted in duplicate by two
reviewers into structured forms. Extracted items included
study characteristics, patient characteristics and outcome
results. For sulfonylurea monotherapy and sulfonylurea
added on to insulin, the primary outcome was the mean
difference between the treatment and comparator group
HbA1c levels at the end of the trial.
After data extraction, we chose the mode of analysis to
maximise the number of data directly available without
imputation. For the analyses of the monotherapy and insulin
trials, the majority of trials reported HbA1c change since
baseline, and we selected this as the outcome for analysis,
imputing it from endpoint data where necessary (one trial).
For the analysis of oral combination trials, the majority of
trials reported endpoint data, and we selected this for anal-
ysis, imputing it from change data where necessary (one
trial). If SDs were not reported, they were imputed by
averaging reported SDs from other trials in the same com-
parison. To check sensitivity to these approximations, we re-
ran analyses excluding trials in which these were necessary
and obtained broadly similar results (ESM Table 1). If
median HbA1c instead of mean was reported, this was used
as an approximation to mean HbA1c.
All of the trials covered in this review reported HbA1c
units as a percentage of total haemoglobin standardised to
the methods of the DCCT. Results are therefore reported in
DCCT units as a percentage and have been converted into
the new SI units using International Federation of Clinical
Chemistry and Laboratory Medicine units of millimoles per
mole of haemoglobin. Other outcomes extracted and
assessed in post hoc analyses were total number of adverse
events, number of hypoglycaemic events, withdrawal due to
adverse events, number of serious adverse events, change in
insulin dose and change in body weight.
Statistical analysis Analysis was performed using a DerSi-
monian and Laird random effects meta-analysis in Stata
version 11.1 (Stata Corporation, College Station, TX,
USA), reporting the mean difference in HbA1c as the pri-
mary outcome. Secondary outcomes were insulin dose in
trials of sulfonylurea and insulin, adverse events and change
in body weight. Because insulin dose was reported both as
international units of insulin and units per kilogram body
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weight, we converted to a standardised mean difference to
allow all the trials to be combined. Adverse events data were
pooled as RRs using the Mantel–Haenszel random effects
model. Data from trials reporting the number of patients
who experienced an adverse event were combined with data
from trials reporting the total number of adverse events
(potentially including multiple episodes for a single patient)
in the meta-analysis. This was achieved by calculating the
number of events per 10 patient-years for trials that reported
results as the total number of adverse events.
One paper [11] reported results from two trials that were
identical in design but compared different doses of glipizide
in each trial. Results for two doses (5 and 20 mg) were
reported as combined mean and SE for both the trials. We
included the results of these trials in the dose-comparison
analysis and kept them as two separate trials as far as
possible in the analysis.
Heterogeneity was reported using the I2 statistic [12].
High heterogeneity was investigated by meta-regression
using the “metareg” command in Stata. We explored in
post-hoc analyses whether the heterogeneity could be
explained by drug type, comparator type, age, BMI, dura-
tion of diabetes, length of follow-up, baseline HbA1c and
year of trial publication. Because of a previous report of an
association between baseline HbA1c and glucose lowering
[10], we also plotted, as a post-hoc analysis, mean reduction
in HbA1c during the trial against mean baseline HbA1c for
the intervention group, for the control group, and for the
difference between the intervention and control groups.
To address possible publication bias, we used Egger’s test
for funnel plot asymmetry [13] wherever possible (including
at least 10 trials in the analysis). We also conducted sensi-
tivity analyses excluding smaller trials (fewer than 100
participants) where possible (ESM Fig. 1). We considered
trial quality using the headings of the Cochrane Risk of Bias
tool [14] as follows. For random sequence generation and
allocation concealment, we included only randomised trials,
and we report the extent of detail on randomisation given by
the trials included. For blinding, we include only studies that
stated they were double-blinded, which we presumed to
imply blinding of outcome assessors as well as blinding of
patients. To address possible attrition bias, we conducted
sensitivity analyses to exclude trials in which fewer than
75% of participants completed the trial. Risk of bias due to
selective reporting is difficult to quantify, but we consider in
the Discussion how it may affect our study.
Results
Searches retrieved a total of 4,308 articles, of which 31 trials
were included in the final analysis (Fig. 1). Searches of
clinical trials registers retrieved a total of 127 trials, from
which no additional trials were identified for inclusion. All
the included trials reported that they randomised patients to
treatments, but only five reported the method of random-
isation. One identified trial of glipizide added on to human
proinsulin [15] was not included in the systematic review
because human proinsulin is not a recognised diabetes treat-
ment despite meeting all other inclusion criteria. Details of
the trials included are shown in Table 1; trials varied in
length from 12 weeks to 3 years, mean patient age varied
from 34 to 66.5 years, and mean baseline HbA1c varied from
4.6% (corresponding to 26.8 mmol/mol) to 13.6%
(corresponding to 125.1 mmol/mol). Of these, nine trials
were included in the analysis of sulfonylurea monotherapy
vs placebo, four trials of sulfonylurea as add-on to another
oral treatment, 17 trials of sulfonylurea in combination with
insulin compared to insulin alone, and four trials in the dose-
comparison analysis.
Sulfonylurea monotherapy trials Two of the nine trials (rep-
resenting 1,151 participants) of sulfonylurea monotherapy
had multiple arms with different doses, which resulted in 12
comparisons. When the data were pooled, the HbA1c level
was 1.51% lower (corresponding to 16 mmol/mol) in the
sulfonylurea group compared with the placebo group (95%
CI 1.25, 1.78, I2=59.8%; Fig. 2). Sensitivity analyses in
which five smaller trials (fewer than 100 participants) were
excluded obtained similar results (ESM Table 1). We inves-
tigated sources of heterogeneity in these trials and found that
the mean age of the participants explained all of the
heterogeneity.
Trials of sulfonylurea added on to fixed-dose oral glucose-
lowering medication Four trials (representing 1,381 partic-
ipants) were included in the meta-analysis of sulfonylurea
4,308 records identified
3,317 records for abstract inspection
215 articles assessed for eligibility
31 trials included
3,102 excluded
Not humans; Not all diabetes; 
Not RCT; 
Not randomised to 
sulfonylurea;








Not possible to separate 
sulfonylurea
991 duplicates removed
Fig. 1 Flow chart of searches
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added on to oral medication. When the data were pooled,
HbA1c was 1.62% lower (95% CI 1.00, 2.24; I
2=94.1%),
corresponding to 18 mmol/mol, in the sulfonylurea group
than in the comparator group (Fig. 3). Because of very high
heterogeneity between these trials, meta-regression was car-
ried out to see whether the heterogeneity could be explained
by other variables. Trial duration was found to reduce the I2
statistic to 47%, and no other factor reduced the I2 by more
than 10%. A sensitivity analysis that excluded one trial of
three arms [16] in which fewer than 75% of participants
completed the trial resulted in a smaller effect size, with
HbA1c 0.96% lower (95% CI 0.47, 1.45) corresponding to
11 mmol/mol in the sulfonylurea-treated groups than in the
comparator groups. Egger’s test found borderline evidence
for publication bias across all 12 monotherapy and oral
combination therapy trials (p=0.052), as shown in ESM
Fig. 1.
Trials of sulfonylurea in combination with insulin Seven-
teen trials (representing 513 participants) of sulfonylurea as
an add-on to insulin were included in the meta-analysis
(Fig. 4). HbA1c level was significantly lower in sulfonylurea
groups compared with placebo in combination with
insulin (0.46% lower; 95% CI 0.24, 0.69, corresponding
to 6 mmol/mol; I2=43.6%). In meta-regression, adjusting for
type of sulfonylurea and duration of diabetes reduced the
heterogeneity (I2=0.0%). Only one trial had more than 100
participants (effect size 0.1%, 95% CI −0.21, 0.41%). Egger’s
Fig. 2 Mean difference in
change in HbA1c of
sulfonylurea monotherapy
treatment vs placebo (boxes)
and pooled estimates
(diamonds) calculated by the
random effects DerSimonian
and Laird method. Horizontal
bars and diamond widths
denote 95% CIs, and box sizes
indicate relative weight in the
analysis
Fig. 3 Mean difference in
change in HbA1c of
sulfonylurea treatment added
on to another oral treatment vs
placebo+other treatment
(boxes) and pooled estimates
(diamonds) calculated by the
random effects DerSimonian
and Laird method. Horizontal
bars and diamond widths
denote 95% CIs, and box sizes
indicate relative weight in the
analysis. Doses in parentheses
are doses of troglitazone, the
background therapy
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test found no evidence for publication bias across the insulin
combination therapy trials (p=0.29), as shown in ESM Fig. 1.
Insulin dose Thirteen of the 17 sulfonylurea and insulin
trials reported the insulin dose. The dose of insulin required
at the end of the trial was significantly lower in the sulfo-
nylurea arm, by 0.55 SD (95% CI 0.25, 0.84), than in the
comparator arm across all trials (ESM Fig. 2). In trials of
type 2 diabetes, the insulin doses in the sulfonylurea-treated
group were significantly lower, by 0.70 SD (95% CI 0.37,
1.02), compared with insulin-only arm. Insulin dose in four
trials of 345 patients with type 1 diabetes did not signifi-
cantly differ between the treatment and comparator arms
(standard mean difference −0.16, 95% CI −0.57, 0.25).
Dose-comparison trials Four trials that conducted a head-to-
head analysis of at least two different sulfonylurea doses were
included in the dose-comparison meta-analysis. Each of the
trials included in the analysis included three or more different
sulfonylurea doses, resulting in nine comparisons (911 partic-
ipants). Pooling of the results (Fig. 5) found no statistically
significant evidence that higher doses of sulfonylurea reduce
HbA1c more than lower doses (pooled mean difference 0.05,
95% CI −0.17, 0.26). Some trials used doses of sulfonylurea
that would be considered high in both arms (according to the
British National Formulary [17]). We therefore conducted a
sensitivity analysis excluding these trials and obtained similar
results: mean difference for glimepiride 0.35 (95% CI −0.05,
0.75), and for glipizide −0.10 (CI −0.58, 0.39).
Adverse events Figure 6 shows the adverse events, serious
adverse events and hypoglycaemic events as reported by the
trials. Seven trials reported the total number of adverse
events, or the number of patients who experienced an ad-
verse event. Adverse events were defined as any event that
occurred after the initiation of treatment. There was no
significant difference in the number of adverse events in
the sulfonylurea-treated group compared with the compara-
tor groups (RR 1.10, 95% CI 0.94, 1.29), and a non-
significant increase in the number of serious adverse events
(reported in five trials) in the sulfonylurea-treated groups
(RR 1.66, 95% CI 0.78, 3.50). Ten trials reported the num-
ber of mild-to-moderate hypoglycaemic episodes (defined
as either patient-reported symptoms or blood glucose levels
below a threshold of 3.1–3.3 mmol/l [55–60 mg/dl] for two
trials), and there were significantly more events in the
sulfonylurea-treated group than in the comparator groups
(RR 2.41, 95% CI 1.41, 4.10). None of the trials reported
any severe hypoglycaemic events requiring third-party as-
sistance. There was no significant difference in the number
of patients who withdrew from the trials due to adverse
events (reported in eight trials) between the sulfonylurea-
treated and comparator arms (RR 0.88, 95% CI 0.56, 1.38;
data not shown).
Change in body weight Twelve trials reported a change in
body weight over the course of the trial. Pooling the results
gave a mean increase in weight of 2.31 kg (95% CI 1.31,
3.32) in the sulfonylurea-treated groups compared with
comparator groups (results not shown).
Baseline HbA1c To explore how baseline HbA1c levels
could be associated with the change in HbA1c, we plotted
effect size against the mean baseline HbA1c for each trial
Fig. 4 Mean difference in
change in HbA1c of
sulfonylurea treatment added
on to insulin treatment vs
insulin+placebo (boxes) and
pooled estimates (diamonds)
calculated by the random
effects DerSimonian and Laird
method. Horizontal bars and
diamond widths denote 95%
CIs, and box sizes indicate
relative weight in the analysis
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(Fig. 7). Although the reduction in HbA1c in the intervention
group appeared to be greater in trials with a higher mean
baseline HbA1c, a similar pattern was seen within the
control groups. The difference in HbA1c reduction between
the intervention and control group did not appear to be
related to mean baseline HbA1c.
Fig. 5 Mean difference in
change in HbA1c of higher
sulfonylurea dose vs lower
sulfonylurea dose (boxes) and
pooled estimates (diamonds)
calculated by the random
effects DerSimonian and Laird
method, stratified by
sulfonylurea type. Horizontal
bars and diamond widths
denote 95% CIs, and box sizes
indicate relative weight in the
analysis. qd, once daily, bid,
twice a day
Fig. 6 Relative risk of total
adverse events, serious adverse
events and hypoglycaemic
events during trials of
sulfonylurea treatment vs
comparator (boxes) and pooled
estimates across trials
(diamonds) calculated by the
fixed effects inverse variance
(I–V) method in patients with
diabetes. Horizontal bars and
diamond widths denote 95%
CIs, and box sizes indicate
relative weight in the I–V
analysis
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Discussion
This systematic review of double-blinded, randomised con-
trolled trials found that sulfonylurea monotherapy reduced
HbA1c by an average of 1.5% (16 mmol/mol), and sulfonyl-
urea in combination other oral medications reduced HbA1c
by 1.6% (18 mmol/mol) compared with placebo groups.
Sulfonylurea treatment in combination with insulin resulted
in a smaller reduction in HbA1c, with the greatest reductions
seen in trials of glibenclamide (HbA1c 0.6% or 7 mmol/mol
lower), than insulin treatment alone and resulted in use of a
lower insulin dose for these patients, consistent with other
reports [9]. In our analysis of dose-comparison trials for two
sulfonylurea drugs, glimepiride and glipizide, we were un-
able to demonstrate that higher doses significantly lowered
HbA1c more than lower doses. We found no evidence that
sulfonylurea treatment resulted in an increase in the total
number of adverse events, but we did find that it increased
the number of hypoglycaemic events.
More trials have been identified in this review than in any
previous systematic review, which can be partly explained
by broader inclusion criteria: we included trials of all sizes
in our review, did not restrict the review to English-language
papers and included patients with type 1 diabetes. We spe-
cifically included trials in which the sulfonylurea dose was
kept constant, which has allowed us to examine the dose–
effect relationship; this is the first time head-to-head dose
comparison trials have been combined in a meta-analysis.
The reduction in HbA1c from sulfonylurea treatment
found in this review is greater than the effect size observed
in another systematic review [6] and within the range sug-
gested in an American Diabetes Association consensus re-
port [4]. Of six trials included in the previous systematic
review [6], only two of these were eligible for inclusion in
our review [5, 18] because of protocol-permitted sulfonyl-
urea dose changes in the other four trials. Newer agents for
blood glucose control have been shown in a recent review to
reduce HbA1c by up to 1% [19]. Our results suggest that
sulfonylureas are at least as effective as these newer agents
in lowering HbA1c; in addition to this, they are less expen-
sive [2]. We have found that sulfonylurea treatment may
result in more hypoglycaemic episodes and an increase in
body weight; this is consistent with known effects of these
medications [20, 21]. We observed no relationship between
effect size and baseline HbA1c when examining the differ-
ence between the reduction in the active treatment and
control groups in the trials (Fig. 7c). Although the reduction
within the trial intervention arms was greater for those trials
with a higher baseline HbA1c we also observed a reduction
in the trial control arms, perhaps attributable to regression to
the mean [22]. A previous systematic review that found an
association between response and baseline HbA1c [10] consid-
ered only trial arms that involved an active glucose-lowering
therapy.
This review has several limitations. First, many of the
trials included were relatively small (fewer than 100 partic-
ipants), which may have led to publication bias, particularly
in the insulin trials. Second, we observed moderate hetero-
geneity in the monotherapy and insulin trials (I2 approxi-
mately 40%), and heterogeneity was high (I2>90%) in the
oral combination trials. Meta-regression suggests that this
may be largely attributable to a differing trial duration, with
greater HbA1c lowering in shorter trials, but meta-regression
results can be subject to confounding and should not be
overinterpreted. Third, our analysis is of glycaemic control
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Fig. 7 (a) Sulfonylurea group−change vs baseline HbA1c. (b) Com-
parator group−change vs baseline HbA1c. (c) Difference in HbA1c vs
mean baseline HbA1c by treatment type. Circles represent monotherapy
trials, triangles represent oral therapy combination trials and diamonds
represent insulin combination trials. Marker size is proportional to trial
size
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glycaemia, HbA1c, has a well-recognised association with at
least the microvascular complications of diabetes. Finally,
follow-up times for the trials included were short: only six
trials followed up patients for longer than 6 months and one
trial for longer than a year [23], meaning that we have only
been able to assess short-term outcomes. Furthermore, the
trials identified for inclusion in this review were relatively
old, only three trials having been published in the past
decade [18, 24, 25]. This reflects the fact that sulfonylureas
are established in the treatment of diabetes.
We have been unable to demonstrate a dose-comparison
effect, but this result needs to be interpreted with caution as
our analysis only included four trials with two different
sulfonylureas; there may be a therapeutic range within
which an increase in dose does further reduce the HbA1c,
which was not possible to examine in this review. Our
review has focused on changes in glycaemic control and
short-term adverse events, and therefore cannot contribute
to the debate about the possible advantages of newer sulfo-
nylureas [26] over the sulfonylureas used in earlier trials, for
which the findings of University Group Program [27] and
the United Kingdom Prospective Diabetes Study [28] have
suggested an association with adverse effects. Instead, we
have sought to quantify the glycaemic lowering of sulfony-
lureas in order to provide a context for understanding similar
reviews of newer oral glucose-lowering agents.
Many of the trials were of short duration, which may be
because we only included trials of a fixed dose of sulfonyl-
urea. This has enabled us to undertake a dose-comparison
analysis and to interpret each trial as the effect for dosage
used. We restricted inclusion to trials of fixed-dose sulfo-
nylurea, which facilitated interpretation including a dose-
comparison analysis; however, the rates of hypoglycaemia
in trials using fixed-dose protocols may not be typical of
rates in clinical practice, in which doses can be adjusted
over time. Because of the short trial duration, we are unable
to comment on the expected duration of effect of sulfonyl-
urea treatment [29]. We have included only double-blinded
randomised controlled trials in our review to minimise bias,
although most of the trials included did not report details of
the method of randomisation or allocation concealment.
Exclusion of a single trial with a high attrition rate [16]
from the oral combination trials resulted in a reduced effect
size from 1.6% to 1% lower HbA1c in the treatment group.
The exact size of the effect estimate in this group therefore
needs to be interpreted with caution. We could not find any
evidence for reporting bias for the primary outcome, HbA1c.
However reporting of adverse events between trials was
inconsistent, so these results may potentially be affected
by reporting bias [14].
We have demonstrated in this review that prescribing
sulfonylureas either alone or added on to another oral med-
ication will effectively reduce HbA1c by around 1.5%, but
we found no evidence that higher sulfonylurea doses result
in a further reduction in HbA1c, although this may be an
effect of the dose ranges used in the trials. The effect of
sulfonylurea treatment on patients already taking insulin is
more modest, although treatment does result in a significant
reduction in both HbA1c and insulin dose. As there is no
evidence for increased effectiveness at higher doses, and as
sulfonylureas are associated with adverse events such as
hypoglycaemic episodes, low-dose sulfonylureas may be
preferred in many cases without titration to maximal dose.
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